Author Archives: Julian Upton
By Julian Upton | Published: March 6, 2013
Teva’s accession to the exclusive group that is the Pharma Top 10 is further proof, according to IMS Health, that branded pharma needs to renounce its product-protected past and embrace the patient-led, specialty-focused future. As the first non-western, non-innovative-core company to enter pharma’s global Top 10, according to IMS Health research, Teva’s rise to prominence […]
By Julian Upton | Published: February 20, 2013
Cuts to US global health and research programs for diseases such as AIDS, tuberculosis and malaria risk derailing the innovations crucial to fighting these diseases, according a new report by the Global Health Technologies Coalition.
By Julian Upton | Published: January 2, 2013
In its new study on pharma market growth in Africa, IMS Health highlights three ‘rising star’ countries from the continent’s sub-Saharan region.
By Julian Upton | Published: November 14, 2012
Greece took its part on Wednesday in the latest widespread strikes against austerity measures that swept across Europe, throwing travel networks into disarray and sparking violent clashes between police and workers. But for once Greece wasn’t at the forefront of the misery as the country has been thrown a couple more lifelines — not least […]
By Julian Upton | Published: July 25, 2012
Industry is finding it harder to secure market access and payer uptake for new products. Innovative contracting may offer a solution. But is it working? Andrea Sobrio reports. How can a pharmaceutical company convince payers that a new treatment is worth budgeting for? Many companies have shifted the weight of their resources to payers and […]